Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Institute Report
Emerging Biopharma’s Contribution to Innovation
Jun 13, 2022
To download files you must give consent to process your personal data by clicking the "Accept" button below.

Web Summary

The majority of biomedical innovation is developed by emerging biopharma (EBP) companies, many of which have never marketed a therapy before. Over time, those companies either successfully bring their products to market or, in many cases, their assets or whole companies are acquired by others. These EBP companies are at the root of early-stage drug development and their performance, the environment in which they operate, and their relationship to other stakeholders in the health system play a critical role in determining the future of many novel therapies and health technologies.

This report is intended to inform executives from these emerging biopharma companies (EBPs), their investors, the large pharma company executives who engage with EBPs and often purchase their assets, as well as policymakers focused on the overall innovation ecosystem. It also has a global focus – as innovation knows no borders – and includes novel analytics across a range of relevant topics.

The report provides clarity on the current landscape of EBP companies and their emerging product pipelines, as well as associated clinical trial activity and levels of trial success. In addition, the report focuses on the financial deals, technology, and approaches to enable and accelerate these companies’ efforts, profiling the drugs these companies have launched or originated, and an assessment of the success of launches in recent years, including nuances beyond simply sales uptake.

Key findings

  • Emerging biopharma companies are responsible for a record 65% of the molecules in the R&D pipeline without a larger company involved, up from less than 50% in 2016 and 34% in 2001
  • The number of products filed with the FDA by emerging biopharma companies has grown four-fold over the last decade and now accounts for 42% of products filed with the FDA, up from 11% in 2012
  • EBPs headquartered in China now account for 17% of the overall EBP innovation pipeline, up from 6% just five years ago
  • A significant portion of oncology drug development comes from emerging biopharma companies, with oncology representing 39% of the emerging biopharma pipeline and more than 1,500 oncology products in development
  • Emerging biopharma companies are more focused on oncology, infectious disease, and vaccines than their larger counterparts, but less on neurology and immunology

Other Findings

  • The number of products under development by emerging biopharma companies has doubled since 2016 despite slower growth in 2021, with 90% of emerging biopharma R&D activity concentrated in five major geographies.
  • U.S.-headquartered EBP companies continue to account for nearly half of the pipeline, although this share has declined slightly in recent years from a peak of 52% in 2016 to 46% in 2021.
  • China-headquartered EBP companies have seen significant growth in the pipeline in recent years with 456% growth since 2016. China-headquartered companies now represent 17% of the EBP pipeline, up from 6% five years ago, highlighting the increasing contribution of Chinese companies to innovation in drug development.
  • The number of deals among companies has been rising over the last five years with emerging biopharma companies becoming more involved.
  • In 2021, 90% of all deal activity involved an emerging company, up from 81% five years ago.
  • A significant portion (62%) of deals is between emerging biopharma companies and do not involve larger companies, with a rising degree of emerging companies partnering and not involving larger companies.
  • Emerging biopharma companies sponsored 3,386 clinical trials starting in 2021, nearly triple that of a decade ago and potentially an understatement as this does not include trials where these companies may partner with a larger company.
  • Emerging biopharma sponsored trials have been driving growth in the number of trial starts over the last decade as total trial starts grew 43% since 2011, with EBP sponsored trials growing 193% over the same period and offset by a decline in large pharma sponsored trial starts of 33%.
  • Emerging biopharma companies sponsored 59% of trial starts in 2021, up from 29% a decade ago, while large pharma companies’ in-house trials showed the inverse pattern, dropping from 59% in 2011 to 28% in 2021.
  • Dynamics of the development and sale of companies or specific drugs are reflected in the launch trends over the past decade.
  • EBP-originated NAS represent 55% of NAS in the past decade, and when launching, EBP companies were the FDA filing company for 76% in 2021 and 62% over the past five years, up from an average 42% in the prior five years.
  • A greater share of NAS are being launched by EBP companies as they increasingly target niche and rare disease targets, potentially making commercialization more achievable by companies with fewer resources.
  • Emerging biopharma companies are consistently the source of new products with the highest sales, but most often when they are launched by a larger company.
  • EBP originated products have generally achieved lower sales when they launch themselves compared to when larger companies launch the products.
  • For launches over the five years from 2016–2020, the most successful drugs were those originated by emerging biopharma companies and launched by larger companies, with the median sales at the end of the second year on the market seven times higher than other launches.

Related solutions

Industry Segments

See how we partner with organizations across the healthcare ecosystem, from emerging biotechnology and large pharmaceutical, to medical technology, consumer health, and more, to drive human health forward.

Contact Us